



**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91-22) 2826 6000  
Fax: (91-22) 2826 7337  
Website: in.pg.com

November 2, 2022

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001  
**Ref:- Scrip Code:- 500459**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai – 400051  
**Ref:- Scrip Code:- PGHH**

Dear Sir / Madam,

**Sub:- Unaudited Financial Results for the quarter ended September 30, 2022**

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commence at 7.30 pm and end at 8.05 pm), the Unaudited Financial Results for the quarter ended September 30, 2022 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended September 30, 2022;
- b. Press Release; and
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended September 30, 2022 furnished by Statutory Auditors of the Company.

Kindly take the same on record. Thanking you.

For **Procter & Gamble Hygiene and Health Care Limited**

**Ghanashyam Hegde**  
**Company Secretary and Executive Director**



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER 2022

(₹ in Lakhs)

Particulars	(1)	(2)	(3)	(4)
	Three Months Ended 30th Sept 2022	Preceding Three Months Ended 30th June 2022	Corresponding Three Months Ended 30th Sept 2021	Year Ended 30th June 2022
	(Unaudited)	(Audited) Refer Note 4 below	(Unaudited)	(Audited)
<b>1 Income</b>				
Sale of products	1 04 092	75 565	1 05 605	3 79 245
Other operating revenues (Refer Note 2)	397	2 073	225	10 847
<b>2 Revenue from operations</b>	<b>1 04 489</b>	<b>77 638</b>	<b>1 05 830</b>	<b>3 90 092</b>
<b>3 Other income</b>	<b>673</b>	<b>563</b>	<b>580</b>	<b>2 432</b>
<b>Total income (2+3)</b>	<b>1 05 162</b>	<b>78 201</b>	<b>1 06 410</b>	<b>3 92 524</b>
<b>4 Expenses</b>				
a) Cost of raw and packing materials consumed	26 630	21 071	34 304	1 26 034
b) Purchases of stock-in-trade (Traded goods)	21 142	17 368	1 385	30 545
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	( 4 441)	( 538)	( 268)	( 650)
d) Employee benefits expense	5 126	4 229	5 616	21 434
e) Finance costs	95	84	59	1 119
f) Depreciation and amortization expense	1 396	1 418	1 269	5 288
g) Advertising & sales promotion expenses	15 569	9 692	12 336	47 124
h) Other expenses	19 065	19 107	22 325	82 616
<b>Total expenses</b>	<b>84 582</b>	<b>72 431</b>	<b>77 026</b>	<b>3 13 510</b>
<b>5 Profit before tax (2+3-4)</b>	<b>20 580</b>	<b>5 770</b>	<b>29 384</b>	<b>79 014</b>
<b>6 Tax expense</b>				
a) Current tax	5 415	1 516	7 864	21 950
b) Deferred tax	( 276)	( 61)	( 309)	( 1 282)
c) Prior year tax adjustments	----	60	----	771
	<b>5 139</b>	<b>1 515</b>	<b>7 555</b>	<b>21 439</b>
<b>7 Profit for the period (5-6)</b>	<b>15 441</b>	<b>4 255</b>	<b>21 829</b>	<b>57 575</b>
<b>8 Other comprehensive income</b>				
Items that will not be reclassified to profit or loss:				
Re- measurement of the defined benefit plans	182	82	45	729
Income tax effect on above	( 46)	( 20)	( 11)	( 183)
<b>Total other comprehensive income for the period</b>	<b>136</b>	<b>62</b>	<b>34</b>	<b>546</b>
<b>9 Total comprehensive income for the period (7+8)</b>	<b>15 577</b>	<b>4 317</b>	<b>21 863</b>	<b>58 121</b>
<b>10 Paid-up equity share capital (Face Value ₹ 10 per equity share)</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>
<b>11 Other Equity</b>				<b>70 511</b>
<b>12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :</b>				
a) Basic	47.57	13.11	67.25	177.37
b) Diluted	47.57	13.11	67.25	177.37
<b>See accompanying notes to the financial results</b>				

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on November 2, 2022 and have been subjected to a limited review by the Statutory Auditors of the Company.
- Other operating revenues for the current quarter, quarter and the year ended June 30, 2022 includes an amount of ₹ 209 lakhs ₹ 1 911 lakhs and ₹ 10 110 lakhs respectively on account of sale of materials consequent to the change in the business model from toller to contract manufacturing.
- The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.
- The figures for the preceding three months ended June 30, 2022 are the balancing figures between the audited figures in respect of the full financial year ended June 30, 2022 and the year to date figures upto the third quarter of that financial year.
- Previous period figures have been regrouped / reclassified wherever necessary.

For and on behalf of the Board of Directors  
Procter & Gamble Hygiene and Health Care Limited

Vaidyanathan  
Digitally signed by  
Vaidyanathan  
Viswanathan  
Date: 2022.11.02  
20:10:12 +05'30'  
Lalgudi  
LV Vaidyanathan  
Managing Director

Place: Goa

Date: November 2, 2022

# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

REVIEW REPORT TO

THE BOARD OF DIRECTORS

PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED** ("the Company") for the quarter ended September 30, 2022, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, (initialled by us for identification). This Statement, which is the responsibility of the Company's Management, has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 2, 2022, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Attention is drawn to the fact that the figures for the three months ended June 30, 2022 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the end of the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **KALYANIWALLA & MISTRY LLP**  
**CHARTERED ACCOUNTANTS**

Firm Reg. No.: 104607W / W100166

  
Roshni R. Marfatia  
**PARTNER**

M. No.: 106548

UDIN: 22106548BBVMLZ7782



Goa, November 2, 2022.

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001  
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275



**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai - 400099  
Tel: (91-22) 2826 6000  
Fax: (91-22) 2826 7337  
Website: in.pg.com

**Procter & Gamble Hygiene and Health Care Ltd. announces first quarter results**

**Mumbai, November 2, 2022:** Procter & Gamble Hygiene and Health Care Ltd. announced today its financial results for the quarter ended September 30, 2022. In a challenging cost and operating environment, the company delivered sales of ₹ 1045 crores, down 1% vs year ago, due to post-Covid normalization of demand. Profit After Tax (PAT) stood at ₹154 crores, down 29% vs year ago, behind top-line impact and significant effect of commodity cost inflation. Compared to the corresponding pre-covid quarter three years ago, company sales are up 23% and PAT is up 12%. The company continues to maintain market share leadership across both Feminine Hygiene and Healthcare categories.

**LV Vaidyanathan, Managing Director, Procter & Gamble Hygiene and Health Care Ltd.** shared, *"In a challenging macro-economic environment, we delivered resilient results in the quarter by focusing on our integrated growth strategies. We believe they remain the right strategies to navigate through the near-term challenges and help us deliver in line with our aim to drive balanced growth."*

**About Procter & Gamble Hygiene and Health Care Limited**

Procter & Gamble Hygiene and Health Care Ltd. (PGHHCL) is one of India's leading FMCG companies that has in its portfolio WHISPER – India's leading Feminine Hygiene brand, and VICKS – India's No. 1 Health Care brand and Old Spice. The company has carved a reputation for delivering high quality, value-added products to meet the needs of consumers. PGHHCL is committed to making every day in the lives of Indian consumers better through superior value propositions. Please visit [in.pg.com](http://in.pg.com) for the latest news.

**For details contact: Madison Public Relations:**

Malika Bhavnani +91 9820496099; [malika.bhavnani@madisonpr.in](mailto:malika.bhavnani@madisonpr.in)